President Donald Trump has signed an executive order April 18 to accelerate research, approval and access to psychedelic drugs, including ibogaine compounds, for serious mental illnesses.
The policy comes amid ongoing mental health challenges, including over 14 million American adults with serious mental illness and suicide rates that increased 37% from 2000 to 2018, according to an April 18 White House news release.
Several states are funding their own research programs and clinical trials on ibogaine.
Here are four things to know:
- The order prioritizes FDA review of psychedelic drugs that have received breakthrough therapy designation and directs issuance of vouchers for psychedelic drugs that have designated as a breakthrough therapy.
- The FDA and Drug Enforcement Administration are tasked with creating pathways for eligible patients to access psychedelic drugs under the Right to Try Act.
- HHS will allocate at least $50 million from existing funds through the Advanced Research Projects Agency for Health to support state programs advancing these therapies.
- Federal agencies, including HHS, FDA and the Department of Veterans Affairs, are directed to expand clinical trial participation, data sharing and real-world evidence generation.
The post Trump order to fast-track psychedelics for mental illness: 4 notes appeared first on Becker's Hospital Review | Healthcare News & Analysis.
Source: Read Original Article
